Pulmonary Nodule & Lung Cancer Screening
Incidental pulmonary nodules are found on ~30% of chest CTs. Most are benign. The key is risk-stratifying: size, morphology, growth, and patient risk factors determine surveillance vs biopsy vs resection.
🔍 Nodule Workup
Fleischner Society Guidelines (2017) -Solid Nodules
| Size | Low Risk (< 5% malignancy) | High Risk (≥ 5% malignancy) |
|---|---|---|
| < 6 mm | No follow-up needed | Optional CT at 12 months |
| 6–8 mm | CT at 6–12 months, then consider CT at 18–24 months | CT at 6–12 months, then CT at 18–24 months |
| > 8 mm | CT at 3 months, PET-CT, or tissue sampling depending on clinical probability | |
High-Risk Features
- Patient: smoking history, older age, family history of lung cancer, prior cancer, occupational exposures
- Nodule: upper lobe location, spiculated margins, growth on serial imaging, part-solid morphology, > 8 mm
Ground-Glass and Part-Solid Nodules (GGN/PSN)
- Pure ground-glass < 6 mm: no follow-up
- Pure ground-glass ≥ 6 mm: CT at 6–12 months, then q2 years × 5 years
- Part-solid (mixed) ≥ 6 mm: CT at 3–6 months. If solid component ≥ 6 mm and persists → PET or biopsy. Part-solid nodules have the highest malignancy rate of any morphology.
Stability for 2 years on serial CT does NOT guarantee benignity for ground-glass nodules -GGNs (often adenocarcinoma in situ) can be indolent for years before becoming invasive. Follow for 5 years minimum.
🔬 Lung Cancer Screening
LDCT Screening Criteria (USPSTF 2021)
- Age 50–80 years
- ≥ 20 pack-year smoking history
- Currently smoke or quit within the past 15 years
- Annual low-dose CT (LDCT) -no IV contrast
NLST, 2011: LDCT screening reduced lung cancer mortality by 20% vs chest X-ray. NELSON, 2020: confirmed 24% reduction in lung cancer mortality in men, 33% in women.
Shared decision-making required. Discuss benefits (mortality reduction), harms (false positives, radiation, anxiety, unnecessary procedures), and the importance of smoking cessation (which reduces mortality far more than screening).
📋 On Rounds
Which nodule morphology has the highest malignancy rate?
Part-solid (mixed ground-glass and solid) nodules. They have a malignancy rate up to ~60% if they persist -higher than either pure solid or pure ground-glass nodules. The solid component usually represents the invasive component of an adenocarcinoma, while the ground-glass component represents in situ or minimally invasive disease.
When do you get a PET-CT for a pulmonary nodule vs just follow-up CT?
PET-CT is indicated for solid nodules ≥ 8 mm with intermediate probability of malignancy (5–65% based on clinical risk). PET has ~90% sensitivity for malignancy but false negatives occur with: (1) nodules < 8 mm (below PET resolution), (2) GGOs/lepidic adenocarcinoma (low metabolic activity), (3) carcinoid tumors. False positives occur with: infection (TB granulomas, fungal), inflammation, sarcoidosis.
What makes a pulmonary nodule more likely to be malignant?
Higher risk features: (1) Size: > 8 mm (malignancy risk increases exponentially with size -6 mm = 1%, 20 mm = 15-20%), (2) Morphology: part-solid (HIGHEST malignancy rate of any type), spiculated margins, irregular shape, (3) Location: upper lobe (lung cancer more common), (4) Growth: any growth on serial imaging is concerning (doubling time 20-400 days for malignancy vs > 400 for benign)
How do you counsel a patient about an incidental pulmonary nodule?
This is a common and anxiety-provoking conversation. Key points: (1) Most nodules are benign -even in smokers, a 6 mm nodule has only ~1% chance of malignancy. Explain this clearly. (2) Follow-up is about tracking change -"we're watching to see if it grows. If it stays the same size over 2 years, it's almost certainly not cancer." (3) Specific follow-up plan with dates -"you'll need a repeat CT scan in [3/6/12] months.
Clinical Examples
📋 Case 1, Incidental Solid Nodule in a Smoker
Patient: 58M, 30-pack-year smoker. CT chest for cough reveals incidental 14 mm solid RUL nodule with spiculated borders. No prior CT for comparison. No symptoms concerning for malignancy.
Key findings: High-risk features: > 8 mm, solid, spiculated margins, upper lobe location, smoker > 30 pack-years. Fleischner Society guidelines: solid nodule > 8 mm in high-risk patient → PET/CT or tissue sampling.
Management:
- PET/CT, FDG avidity suggests malignancy (SUV > 2.5 has ~90% sensitivity for malignant nodules > 8 mm)
- If PET-avid: CT-guided biopsy or navigational bronchoscopy for tissue diagnosis
- If biopsy confirms NSCLC: staging with brain MRI → surgical resection if early stage (lobectomy + mediastinal lymph node dissection)
- If PET-negative: CT surveillance at 3 months, then annually × 2-3 years (false negatives occur with low-grade adenocarcinoma)
- Low-dose CT lung cancer screening annually (meets USPSTF criteria: age 50-80, ≥ 20 pack-years)
Teaching point: Spiculated margins are the single most concerning morphologic feature for malignancy (~90% PPV). Smooth, well-defined margins favor benign, but do not rule out cancer. Size + morphology + risk factors together determine the approach.
📋 Case 2, Small Incidental Ground-Glass Nodule
Patient: 45F never-smoker. CT PE study (negative for PE) incidentally shows a 6 mm pure ground-glass nodule (GGN) in the LLL. No solid component. No prior imaging.
Key findings: Pure GGN 6 mm, these are almost always preinvasive adenocarcinoma (AIS/MIA) or atypical adenomatous hyperplasia if persistent. Very slow-growing, doubling time often > 800 days. Low risk of metastasis even if malignant.
Management:
- Fleischner 2017: 6 mm pure GGN → follow-up CT at 6-12 months to confirm persistence
- If persistent: CT annually × 5 years (these grow very slowly, long surveillance needed)
- No PET/CT (pure GGNs are often PET-negative even if malignant, low metabolic activity)
- No biopsy unless growing or developing solid component
- If develops solid component (> 5 mm solid): reclassify as part-solid → more aggressive workup
Teaching point: Pure GGNs are indolent, even when malignant (AIS/MIA), they rarely metastasize. The danger is the development of a solid component, which transforms the prognosis. Part-solid nodules with solid component > 5 mm have the highest malignancy risk of all nodule types.
📋 Case 3, Multiple Nodules on Lung Cancer Screening
Patient: 62M, 35-pack-year smoker. Annual LDCT screening shows 3 new nodules: 4 mm solid RML, 7 mm solid RUL, and 9 mm part-solid LUL (6 mm solid component). No prior nodules.
Key findings: Multiple nodules with one dominant suspicious nodule (9 mm part-solid with 6 mm solid component). Lung-RADS 4B. The part-solid nodule with substantial solid component is the most concerning, warrants tissue diagnosis.
Management:
- Dominant nodule (9 mm part-solid): PET/CT → if avid, navigational bronchoscopy or CT-guided biopsy
- 4 mm solid: Fleischner → follow-up CT at 12 months (low risk at this size)
- 7 mm solid: short-interval CT at 3 months or PET/CT given smoking history
- If dominant nodule = cancer: full staging → may need PET/CT of all nodules (separate primaries vs metastases)
- Continue annual LDCT screening regardless of this finding
Teaching point: With multiple nodules, manage based on the most suspicious nodule. Part-solid nodules with solid component ≥ 6 mm have the highest malignancy risk (~60%). Multiple nodules in a smoker are more likely separate primary lung cancers than metastases from a single primary.
📣 Sample Presentation
One-Liner
"Ms. Kim is a 55-year-old smoker whose CT chest for cough incidentally found a 12 mm solid right upper lobe pulmonary nodule. No prior imaging for comparison."
Key Points to Cover on Rounds
Incidental 12 mm solid RUL nodule in a smoker -intermediate-to-high malignancy risk. Per Fleischner: solid nodule ≥8 mm → consider CT at 3 months, PET-CT, or tissue sampling depending on clinical probability. Given risk factors (smoker, upper lobe, >8 mm): PET-CT ordered. If PET avid → CT-guided biopsy or surgical excision. If PET negative → CT follow-up at 3, 6, 12, 24 months. Lung-Rads if found on screening LDCT. Patient counseled about findings and follow-up plan documented. Smoking cessation strongly reinforced. Pulmonology referral placed.
🧪 Workup
Workup
See the Overview and Management tabs for the pulmonary nodule workup (Fleischner algorithm by size + morphology + risk, PET-CT for solid nodules ≥ 8mm with intermediate probability, biopsy vs serial CT decision, and Lung-Rads for screening-detected nodules).
💊 Medications
Medications
Pulmonary nodule evaluation is primarily diagnostic, there are no disease-specific pharmacotherapies. Agents involved are procedural (contrast for CT/PET, sedatives for biopsy) or directed at confirmed lung malignancy (see Oncology topics for lung cancer-specific regimens).
⚡ Summary
Most Are Benign
Incidental nodules appear on roughly 30% of chest CTs, and the great majority are not cancer. Risk-stratify on size, morphology, growth and patient factors rather than reflexively biopsying or reflexively ignoring. The point of the guidelines is to avoid both extremes.
Follow Fleischner for Solid Nodules
Under 6 mm in a low-risk patient: no routine follow-up. Under 6 mm in a high-risk patient: optional CT at 12 months. 6 to 8 mm: CT at 6 to 12 months, then 18 to 24 months. Above 8 mm: consider CT at 3 months, PET-CT or tissue sampling. These apply to incidental nodules in adults over 35, not to screening findings, immunosuppressed patients or known cancer.
Morphology and Location Change the Probability
Spiculated margins, upper lobe location and growth raise suspicion. Benign calcification patterns, central, laminated, popcorn or diffuse, effectively exclude malignancy, whereas eccentric or stippled calcification does not. Fat within a nodule means hamartoma.
Ground-Glass Nodules Follow Different Rules
Two years of stability does not guarantee benignity. Ground-glass nodules, often adenocarcinoma in situ, can be indolent for years before becoming invasive, so follow them for at least 5 years. A part-solid nodule with a growing solid component is the concerning pattern, and the solid portion size is what predicts invasiveness.
PET Has Real Limits
It is unreliable below about 8 mm, and it is falsely negative in ground-glass lesions, carcinoid and mucinous adenocarcinoma. False positives occur in infection, granulomatous disease and inflammation, which matters greatly in regions endemic for histoplasmosis and coccidioidomycosis. A negative PET in a suspicious nodule does not close the case.
Screen the Right Population
Annual low-dose CT from 50 to 80, with a 20 pack-year history, in current smokers or those who quit within 15 years (USPSTF 2021, which lowered the age and pack-year thresholds). Stop screening once 15 years have passed since quitting, or when a health problem limits life expectancy or the willingness to have curative surgery.
Screening Requires Shared Decision-Making
Discuss the mortality benefit alongside the harms: false positives, incidental findings, radiation, anxiety and unnecessary procedures. Smoking cessation reduces mortality far more than screening does, so the screening visit is also the cessation visit, and framing it that way is the highest-yield part of the conversation.
Choose the Diagnostic Route by Location and Fitness
Peripheral lesions: CT-guided transthoracic biopsy, with a real pneumothorax rate. Central lesions: bronchoscopy, increasingly navigational. A high-probability nodule in a good surgical candidate may go straight to resection, since a negative biopsy in that setting rarely changes the plan. Discuss at a multidisciplinary meeting, and always compare with prior imaging first, which resolves many nodules without any further test.
🔍 Overview
Overview -Pulmonary Nodule & Lung Cancer Screening
See the tabs above for the complete clinical reference: Workup, Management, Medications, Monitoring, Rounds, Summary, and One Pager.
📄 One Pager
Text version
Pulmonology · One Pager
Pulmonary Nodule
Fleischner guidelines for incidental nodules. High-risk features: > 8mm, upper lobe, spiculated, part-solid, smoker. PET-CT for intermediate probability. DOCUMENT and follow up.
Risk Assessment
Size (> 8mm), morphology (part-solid = highest malignancy rate, spiculated), location (upper lobe), patient factors (smoker, age > 50, FH lung cancer, COPD).
Fleischner Guidelines (Solid Nodule, Low Risk)
< 6 mm: no routine follow-up. 6–8 mm: CT at 6–12 mo, then 18–24 mo. > 8 mm: CT at 3 mo, PET-CT, or tissue sampling. Multiple nodules → follow most suspicious. Part-solid: lower threshold for biopsy; follow 5 years.
Key Actions
CT follow-upPer Fleischner timing
PET-CTIntermediate probability, ≥ 8mm
BiopsyPET-avid or high suspicion
LDCT screeningPer Lung-Rads classification
Pitfalls
- Lost to follow-up (major malpractice risk -document and schedule)
- Part-solid nodules dismissed as benign (highest malignancy rate)
- Not considering malignancy in smoker > 50 with new nodule
- Fleischner applied to screening LDCT (use Lung-Rads instead)
Related Topics
AsthmaCOPD -Chronic ManagementHemoptysisInterstitial Lung DiseaseObstructive Sleep ApneaPFT Interpretation